Biosimilars
-
340B, Biosimilars, Caught my eye, DTC, Employers, FDA, Obesity, Reference Pricing, State-based Reform, ValueAMP is WAC — 2/20/26
Read more: AMP is WAC — 2/20/26We have some new folks around these parts so quick intro. I’m Jennifer Snow. I’ve spent 25 years inside the U.S. pharmaceutical policy world, not watching it from the outside, but sitting in the meetings, reading the rules, and translating what they actually mean for the people whose drugs are on the line. I’m not…
-
340B, Affordable Care Act, Biosimilars, Caught my eye, Drug Prices, Inflation Reduction Act, Insulin, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based Reform, Utilization ManagementAMP is WAC — 2/13/26
Read more: AMP is WAC — 2/13/26I chuckled during the E&C hearing when members were questioning the panelists about the pharmaceutical deals with the Administration. As if these are the people they should be asking. Make a left, make right, go down about a mile – there’s a big white house. Maybe they can help you there. Parallels Between 340B and…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Employers, Medicare Advantage, Pharmacy Benefit Managers, Reference PricingAMP is WAC — 1/22/26
Read more: AMP is WAC — 1/22/26I swear that inside I’m an 8-year-old at times (one that likes to make cocktails, but still), I am so excited about a snowstorm. Real snowfall! Cozy inside time interspersed with time shoveling out alongside neighbors. Watching the kids sled in front of the elementary school. Pulling out the snowshoes and remembering that they aren’t…
-
Affordable Care Act, Alzheimer’s, Biosimilars, Caught my eye, Drug shortages, FDA, Medicaid, Medicare Part D, UncategorizedAMP is WAC — 11/14/25
Read more: AMP is WAC — 11/14/25How is it mid-November? I think of all of the things that need to get done by the end of the year and then try and pull out the productivity schemes (5 choices, pomodoro, eat the frog, etc.) I’ve learned over the years. The problem is that none of these create more time, just make…
-
Biosimilars, Caught my eye, Generics, Health Equity, ICER, Medicare Advantage, Medicare Part D, Obesity, Pharmacy Benefit Managers, State-based Reform, Utilization Management, ValueAMP is WAC — 10/31/25
Read more: AMP is WAC — 10/31/25You won’t be surprised when I tell you that my favorite Halloween costume was when I wore a pair of scrubs with vinyl records attached (Spin Doctor). Yep. Right up there with Freudian slips. This year I will stick to my usual costume: the nice lady who hands out full-size bars to 200+ neighborhood kids.…
-
AMP is WAC — 7/18/25
Read more: AMP is WAC — 7/18/25I have a case of existential dread, and yet the world keeps spinning so let’s do this… Caught my Eye More Cowbell. Late last year I put out a report on biosimilars and it called out how the Inflation Reduction Act could hurt innovation and savings for biosimilars. Here is a report from Matrix Global…
-
Affordable Care Act, Biosimilars, Caught my eye, Employers, Healthcare Costs, Inflation Reduction Act, Medicare Advantage, Medicare Part D, Pharmacy Benefit Managers, Utilization ManagementAMP is WAC — 6/27/25
Read more: AMP is WAC — 6/27/25In case you think I’m opinionated, just know that it could be so.much.worse. I often write something and then hit backspace, backspace, backspace. You’re welcome? Off next week for the 4th of July. Caught my Eye Tradeoffs. Last week USC put out a paper that reviewed how many Medicare Part D beneficiaries will likely pay…
-
AMP is WAC — 6/13/25
Read more: AMP is WAC — 6/13/25Caught my Eye Make Believe. This week we were wondering if the Administration would put out information on what the Most Favored Nation (MFN) would be for drugs; that is what is the best price for each drug in a set of country’s that have a GDP at least 60% of ours. But there have…
-
340B, Alzheimer’s, Biosimilars, Caught my eye, Drug Prices, Generics, Healthcare Costs, Importation, Medicaid, State-based ReformAMP is WAC — 05/23/25
Read more: AMP is WAC — 05/23/25It’s the Friday of Memorial Day weekend, let’s blow this pop (pup?) stand. I’m playing with the format of these posts so let me know what you think. The aim is to be more of a newsletter than a blog, but still give you everything you need to know in just a few minutes a…
-
340B, Biosimilars, CMMI, Drug Prices, Generics, Healthcare Costs, Importation, Insulin, Medicaid, Pharmacy Benefit ManagersDon’t Call it a Comeback
Read more: Don’t Call it a ComebackLet’s wrap up my musings on the President’s Executive Order (EO). Medicaid. Section 6 of the EO directs the Office of Management and Budget (OMB) Director, the Assistant to the President for Domestic Policy, and the Assistant to the President for Economic Policy, in coordination with the Secretary of Health and Human Services (HHS), to…
Latest news
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
- AMP is WAC — 2/6/26
Categories
- 340B (62)
- Affordable Care Act (21)
- Alzheimer's (10)
- Biosimilars (31)
- Caught my eye (101)
- Cell and Gene (5)
- Chevron Deference (2)
- CMMI (26)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (6)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (67)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (76)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (26)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)